## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.3% below STRENGTH zone (3.0-6.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($140.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Quadrant Capital Group LLC Purchases 3,395 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251201T110202 | Somewhat-Bullish | Relevance: 99%
- Quadrant Capital Group LLC increased its stake in Agilent Technologies by 40.2%, purchasing an additional 3,395 shares, bringing their total holdings to 11,846 shares valued at $1.398 million. The medical research company recently beat quarterly earnings estimates with $1.59 EPS and $1.86 billion in revenue, and has raised its quarterly dividend to $0.255. Insider activity shows CEO Padraig Mcdonnell sold 12,490 shares in November.

**2. Agilent Technologies (A): Assessing Valuation Following Strong Q4 Results and Upbeat 2026 Guidance**
- Source: Simply Wall Street | 20251130T120609 | Bullish | Relevance: 99%
- Agilent Technologies (A) reported strong Q4 results and provided upbeat 2026 guidance, leading to a significant increase in its share price. The company's valuation is being assessed, with one narrative suggesting it's 8.4% undervalued at a fair value of $167.57, while a DCF model indicates it might be trading slightly above its estimated fair value at $146.54. Strong growth in pharmaceutical and chemicals/advanced materials end markets, driven by increased global healthcare demand and R&D budgets, is contributing to investor optimism, though supply chain complexities and tightening research budgets remain potential risks.

**3. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: Business Wire | 20251201T132123 | Bullish | Relevance: 99%
- Agilent Technologies Inc. announced the release of new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system. This software extends the system's applicability to GMP-regulated manufacturing and quality control settings, addressing the growing demand for compliant digital lab tools in biopharma and cell therapy. The upgrade features secure user authentication, electronic signatures, and complete audit trails, ensuring data integrity and streamlining regulatory submissions.

**4. Agilent Technologies price driven lower by pivotal resistance - Forecast today - 02-12-2025**
- Source: Economies.com | 20251202T132500 | Somewhat-Bullish | Relevance: 98%
- Agilent Technologies (A) declined after hitting a pivotal resistance level at $153.75, prompting profit-taking despite an overall short-term ascending trend. The stock is attempting to relieve overbought RSI saturation and consolidate positive momentum. A breakout above $153.75 is needed to target the next resistance at $169.50, with a bullish forecast.

**5. Agilent Technologies (NYSE: A) CEO surrenders 1,948 shares for taxes**
- Source: Stock Titan | 20251201T163400 | Neutral | Relevance: 98%
- Agilent Technologies' President and CEO, Padraig McDonnell, surrendered 1,948 shares of common stock on November 26, 2025, to cover tax liabilities arising from the vesting of restricted stock units. This transaction, executed at $154.37 per share, is described as a routine administrative act to satisfy taxes, not an open-market sale. After this surrender, the CEO beneficially owns 66,539 shares of Agilent common stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.7x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.7B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.7 |
| Current P/E | 25.0 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.4% to -3.3% (-7.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >3.0% for momentum thesis). Underperforming sector by 3.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.32% (CS: 18) | Weak |
| RSI_14 | 52.6 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.203x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $148.81
- **Stop Loss:** $140.59 (5.5% risk)
- **Target:** $157.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $18,006.01
- **Portfolio %:** 18.01%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*